J.B. Chemicals & Pharmaceuticals quarterly results

Q4 FY26 · Jan–Mar 2026

₹ crore	Q4 FY26	Q4 FY25	Change
Revenue	904	949	−4.8%
EBITDA	201	226	−11.2%
EBITDA margin	22.2%	23.9%	−1.6 pts
Profit before tax	135	193	−30.2%
Net profit	101	146	−30.4%
EPS	₹6.35	₹9.36	−32.2%

Every quarter

₹ crore except per share

Tap a line for its trend	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Q1 FY24Jun 2023	Earlier quartersAlpha Plus

Expenses
	904	1,065	1,085	1,094	949	963	1,001	1,004	862	845	882	896	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	12.0	18.3	15.3	14.6	14.5	8.0	10.0	5.9	16.6	7.4	7.7	5.6
	916	1,083	1,100	1,108	964	971	1,011	1,010	878	852	889	902
	234	212	225	241	189	200	179	252	177	199	221	219
	103	104	121	149	136	110	150	101	176	78.4	78.2	80.2
	−62.3	13.1	−1.2	−43.7	−3.3	6.7	9.1	−12.9	−52.7	−3.7	−1.4	11.0
	199	191	188	194	177	173	171	167	153	152	148	149
	1.2	1.9	1.4	1.1	1.5	2.6	2.1	5.6	9.4	12.5	10.4	12.1
	50.0	45.4	44.4	42.7	46.4	41.9	41.9	40.8	40.7	34.0	32.2	31.4
	230	248	242	252	225	219	221	217	211	196	192	205
	754	816	821	837	771	754	774	770	714	668	681	708
	201	296	310	301	226	255	271	280	198	223	244	232
	151	250	265	258	180	213	229	240	157	189	211	201
Profit
	162	267	279	272	193	218	237	240	165	184	209	194
	−27.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	135	267	279	272	193	218	237	240	165	184	209	194
	37.7	63.1	65.9	65.6	46.0	46.1	53.9	54.5	29.5	36.2	44.5	40.8
	−4.4	5.9	5.5	3.6	1.4	9.4	8.1	8.5	9.0	14.1	13.6	11.2
	33.3	69.0	71.3	69.2	47.3	55.5	62.0	63.0	38.4	50.4	58.1	52.0
	101	198	208	202	146	162	175	177	126	134	151	142
	101	198	208	202	146	162	175	177	126	134	151	142
	7.3	10.0	5.2	4.3	13.6	−14.9	2.7	7.1	−4.2	1.4	−3.3	−8.5
	109	208	213	207	159	148	177	184	122	135	147	134
	101	198	208	207	146	162	175	—	126	134	155	142
Per share
	₹6.35	₹12.63	₹13.29	₹12.99	₹9.36	₹10.46	₹11.24	₹11.39	₹8.22	₹8.62	₹9.72	₹18.39
	₹6.32	₹12.45	₹13.08	₹12.75	₹9.17	₹10.24	₹11.00	₹11.17	₹8.06	₹8.46	₹9.54	₹18.14
Other comprehensive income — detail
	7.3	10.0	5.2	4.3	13.6	—	—	—	—	—	—	—
	4.4	−1.3	−5.3	−1.3	−0.1	−1.3	−3.3	−1.2	0.4	−1.5	−3.7	−0.2
	1.1	−0.3	−1.3	−0.3	−0.0	—	—	—	—	—	—	—
	—	—	—	—	—	−0.3	−0.8	−0.3	0.1	−0.4	−0.9	−0.1
	4.1	10.9	9.0	5.2	14.9	−14.6	5.0	8.3	−5.1	2.4	−0.7	−8.1
	0.1	−0.1	−0.1	−0.1	1.2	—	—	—	—	—	—	—
	—	—	—	—	—	−0.6	−0.2	0.3	−0.5	−0.1	−0.2	0.3
	109	208	213	—	159	148	177	184	122	135	147	134
Per share — as-filed variants
	₹6.35	₹12.63	₹13.29	₹12.99	₹9.36	₹10.46	₹11.24	₹11.39	₹8.22	₹8.62	₹9.72	₹18.39
	₹6.32	₹12.45	₹13.08	₹12.75	₹9.17	₹10.24	₹11.00	₹11.17	₹8.06	₹8.46	₹9.54	₹18.14
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	630	735	739	747	628	647	662	665	561	571	584	586
	69.7%	69.1%	68.2%	68.3%	66.1%	67.1%	66.2%	66.2%	65.2%	67.6%	66.2%	65.4%
Adjusted (ex-exceptional items) — derived
	162	267	279	272	193	218	237	240	165	184	209	194
	−27.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	122	198	208	202	146	162	175	177	126	134	151	142
	₹7.63	₹12.63	₹13.29	₹12.99	₹9.36	₹10.46	₹11.24	₹11.39	₹8.22	₹8.62	₹9.72	₹18.39

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

View

In ₹ Crore except Per Share 3 Months Ending	Q1 FY24 30/06/2023	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026
Revenue from Operations	896.2	881.7	844.5	861.7	1,004.4	1,000.6	963.5	949.5	1,093.9	1,084.9	1,064.7	904.2
Other Income	5.6	7.7	7.4	16.6	5.9	10.0	8.0	14.5	14.6	15.3	18.3	12.0
Total Income	901.8	889.4	851.9	878.4	1,010.3	1,010.6	971.5	964.0	1,108.5	1,100.2	1,083.0	916.2
Expenses
+ Cost of Materials Consumed	218.8	221.4	198.9	177.2	251.6	179.2	200.2	189.0	241.4	225.3	212.0	233.7
+ Purchases of Stock-in-Trade	80.2	78.2	78.4	175.8	101.0	150.1	109.8	136.0	149.4	121.3	104.3	102.8
+ Changes in Inventories	11.0	-1.4	-3.7	-52.7	-12.9	9.1	6.7	-3.3	-43.7	-1.2	13.1	-62.3
+ Employee Benefit Expense	148.8	148.3	151.7	152.7	166.9	170.6	173.3	176.8	194.3	188.3	191.4	198.7
+ Finance Costs	12.1	10.4	12.5	9.4	5.6	2.1	2.6	1.5	1.1	1.4	1.9	1.2
+ Depreciation & Amortisation	31.4	32.2	34.0	40.7	40.8	41.9	41.9	46.4	42.7	44.4	45.4	50.0
+ Other Expenses	205.4	191.8	196.1	210.6	217.4	221.1	218.9	224.6	251.7	241.6	248.1	230.1
Total Expenses	707.5	680.7	667.9	713.8	770.5	774.0	753.5	770.9	836.9	821.1	816.1	754.3
EBITDA	232.1	243.5	223.1	198.1	280.4	270.5	254.5	226.4	300.9	309.6	295.8	201.1
EBIT	200.7	211.4	189.1	157.4	239.6	228.6	212.6	180.0	258.2	265.2	250.5	151.1
Profit
PBT before Exceptional Items	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	161.9
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-27.2
Pretax Income	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	134.7
+ Current Tax	40.8	44.5	36.2	29.5	54.5	53.9	46.1	46.0	65.6	65.9	63.1	37.7
+ Deferred Tax	11.2	13.6	14.1	9.0	8.5	8.1	9.4	1.4	3.6	5.5	5.9	-4.4
Tax Expense	52.0	58.1	50.4	38.4	63.0	62.0	55.5	47.3	69.2	71.3	69.0	33.3
Net Income	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	101.4
+ Net Income — Continuing Ops	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	101.4
+ Other Comprehensive Income	-8.5	-3.3	1.4	-4.2	7.1	2.7	-14.9	13.6	4.3	5.2	10.0	7.3
Total Comprehensive Income	133.8	147.3	135.0	121.9	184.0	177.3	147.6	159.3	206.7	213.0	207.9	108.7
Net Income to Common	142.3	155.1	133.6	126.2	—	174.6	162.5	145.7	206.7	207.8	197.9	101.4
Per Share
Basic EPS	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	6.35
Diluted EPS	18.14	9.54	8.46	8.06	11.17	11.00	10.24	9.17	12.75	13.08	12.45	6.32
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	—	13.6	4.3	5.2	10.0	7.3
+ Items NOT to be Reclassified to P&L	-0.2	-3.7	-1.5	0.4	-1.2	-3.3	-1.3	-0.1	-1.3	-5.3	-1.3	4.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	—	-0.0	-0.3	-1.3	-0.3	1.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.9	-0.4	0.1	-0.3	-0.8	-0.3	—	—	—	—	—
+ Items to be Reclassified to P&L	-8.1	-0.7	2.4	-5.1	8.3	5.0	-14.6	14.9	5.2	9.0	10.9	4.1
+ Tax on Items to be Reclassified	—	—	—	—	—	—	—	1.2	-0.1	-0.1	-0.1	0.1
+ Tax on Items to be Reclassified — alt tag	0.3	-0.2	-0.1	-0.5	0.3	-0.2	-0.6	—	—	—	—	—
Comprehensive Income — Owners of Parent	133.8	147.3	135.0	121.9	184.0	177.3	147.6	159.3	—	213.0	207.9	108.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	6.35
Diluted EPS — Continuing Operations	18.14	9.54	8.46	8.06	11.17	11.00	10.24	9.17	12.75	13.08	12.45	6.32
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	586.2	583.6	570.9	561.5	664.7	662.2	646.8	627.8	746.8	739.4	735.3	630.0
Gross Margin %	65.41	66.18	67.60	65.15	66.17	66.18	67.13	66.12	68.27	68.15	69.06	69.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	194.3	208.7	184.0	164.6	239.8	236.5	218.0	193.0	271.6	279.2	266.9	161.9
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-27.2
Net Income Adj (tax-effected)	142.3	150.6	133.6	126.2	176.8	174.6	162.5	145.7	202.4	207.8	197.9	121.8
EPS Adj	18.39	9.72	8.62	8.22	11.39	11.24	10.46	9.36	12.99	13.29	12.63	7.63
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	1.00	1.00	1.00	1.00	1.00	—	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	15.5	15.5	15.5	15.5	15.5	15.5	15.6	15.6	15.6	15.7	15.7	16.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q4 FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.